For years, consolidation seemed to offer a simple answer to one of pharmaceutical outsourcing’s most persistent problems: fragmentation.
Why manage separate partners for drug substance, drug product, analytical development, fill-finish and packaging when one organisation could cover most, or even all, of the chain?
The logic was persuasive. Fewer suppliers meant fewer contracts, fewer technology transfers, fewer interfaces to manage and, potentially, fewer opportunities for information to be lost between one step and the next.
That logic has not disappeared.
Yet the evolution of pharmaceutical technologies is making the choice considerably less straightforward.
CPHI’s 2026 Outsourcing Outlook Update describes what it calls a “Great Bifurcation” in the CDMO market: on one side, increasingly specialised providers serving technologically demanding niches; on the other, larger organisations seeking to integrate development and manufacturing capabilities across the product lifecycle.
Both models are expanding.
That is precisely what makes the choice interesting.
The appeal of integration
There are obvious advantages to entrusting a programme to a CDMO capable of following it through multiple stages.
A single organisation may coordinate process development, analytical work, scale-up, drug-substance manufacturing, drug-product manufacturing and commercial supply. Transfers between stages can remain within the same corporate system. Project governance may be simpler. Data can move through fewer organisational boundaries.
For sponsors with limited internal manufacturing resources, particularly emerging biotech companies, this can be attractive.
The value goes beyond administrative convenience.
Every transfer creates an interface. At each interface, knowledge has to be translated, documentation aligned, methods transferred and responsibilities renegotiated. A receiving site must understand not only what the process is, but why certain parameters, controls and decisions matter.
The fewer those interfaces, the easier continuity may become.
CPHI notes that the appeal of integrated CDMOs remains strong precisely because pharmaceutical companies increasingly want a smaller number of strategic partners capable of moving assets from development into commercial manufacturing.
Integration can therefore reduce what might be called organisational friction.
But pharmaceutical manufacturing is becoming more technologically fragmented at the same time.
One company, many technologies
The problem becomes visible when the word capability is examined more closely.
A company may legitimately describe itself as an end-to-end CDMO while relying on very different levels of expertise across its portfolio. Excellence in small-molecule API manufacturing does not automatically imply excellence in sterile drug product. Expertise in mammalian cell culture does not guarantee the same depth in ADC conjugation, viral vectors or high-potency containment.
The technologies may sit within the same corporate perimeter without being equally mature.
Nice Insight’s State of the Industry 2026 provides an illuminating example. It tracks more than 500 CDMOs across all modalities, but only five organisations globally are identified as offering the full combination of mammalian production, API synthesis, ADC conjugation and HPAPI fill capabilities. The same analysis counts 99 CDMOs with ADC conjugation capabilities, twice the number identified in 2024.
That gap matters.
Adding capabilities to a portfolio is possible. Building deep expertise across each of them is harder.
Facilities can be acquired. Equipment can be installed. Specialist knowledge accumulates more slowly.
Why specialisation is gaining value
The rise of specialist CDMOs is closely connected to the increasing technical complexity of pharmaceutical pipelines.
Highly potent APIs require sophisticated containment strategies and occupational-safety systems. ADCs combine biologics, chemistry, conjugation and high-potency handling. Cell and gene therapies introduce completely different manufacturing architectures, analytical challenges and supply-chain requirements. Sterile manufacturing continues to move towards advanced barrier technologies, flexible multiproduct facilities and increasingly demanding contamination-control strategies.
These are not simply different production lines.
They involve different bodies of knowledge.
CPHI’s 2026 analysis notes that capacity expansion is increasingly concentrated in high-value niches such as cell and gene therapies, complex injectables and high-containment manufacturing, where demand remains structurally strong and execution matters as much as infrastructure.
Nice Insight reaches a similar conclusion. In its analysis of sterile manufacturing, investment is moving towards isolator-based, multiproduct and flexible facilities. In ADC manufacturing, capability continues to expand rapidly. Yet both areas remain technically demanding and dependent on experienced personnel.
Specialisation becomes valuable because sponsors are not simply buying access to equipment.
They are buying accumulated experience with a specific problem.
Best in class, but at what cost?
This helps explain why Nice Insight identifies an emerging alternative to the one-stop-shop model: best in class within a network.
Instead of choosing a single provider for an entire programme, a sponsor can assemble a group of specialist organisations, each selected for a particular capability.
On paper, the model is compelling.
The strongest API manufacturer produces the drug substance. A specialist develops the formulation. Another provider handles sterile fill-finish. An analytical laboratory covers highly specialised testing. Packaging and clinical supply go elsewhere.
At each stage, the sponsor can select the organisation considered most suitable for the task.
But technical optimisation creates organisational complexity.
Every additional provider introduces a new interface, quality agreement, data flow, timeline and dependency. Someone must coordinate the overall programme. Someone must ensure that the output of one partner is genuinely ready to become the input of the next.
The sponsor may discover that it has become the systems integrator.
This is one of the less visible costs of specialist outsourcing.
Technology transfer becomes the test
The quality of technology transfer often determines whether a specialist network functions as a coherent manufacturing system or simply as a sequence of suppliers.
A transfer is not a shipment of documents.
Process history, deviations, analytical knowledge, tacit operational experience and the reasoning behind critical decisions all need to cross the organisational boundary.
This becomes more difficult as the network expands.
Recent discussions around pharmaceutical manufacturing ecosystems have placed increasing emphasis on structured and early technology transfer, reproducibility and process control. A 2026 industry panel on the innovation ecosystem behind the molecule similarly highlighted data and knowledge transfer as critical to successful scaling across organisations.
That point is easy to underestimate.
The more specialised the outsourcing model becomes, the more valuable interoperability becomes.
A technically excellent CDMO that cannot transfer knowledge effectively may be a poor component of a multi-partner programme.
A network can also diversify risk
There is another side to fragmentation.
Using several specialist partners can prevent excessive dependence on a single organisation.
A vertically integrated CDMO may simplify operations, but it can also concentrate risk. A major quality event, capacity constraint, ownership change or strategic reprioritisation can affect several parts of the programme simultaneously.
A distributed network may offer greater flexibility.
Alternative routes can be developed. Particular stages can be moved independently. Sponsors may retain more freedom to replace one provider without dismantling the entire manufacturing architecture.
The benefit, however, depends on how real that diversification is.
Two apparently independent CDMOs may rely on the same raw-material source, analytical subcontractor or upstream technology. Geographic diversification can also prove superficial when critical inputs remain concentrated in a single region.
Supplier count and resilience are not the same thing.
The hidden variable is governance
The choice between integration and specialisation is therefore not simply technical.
It is organisational.
An integrated CDMO reduces the number of external interfaces but requires the sponsor to understand how well the provider’s internal units actually work together.
A specialist network maximises access to focused expertise but requires stronger coordination across companies.
In both cases, governance becomes critical.
Who owns the programme-level timeline? Who manages dependencies between drug substance and drug product? Who decides when a delay at one site requires changes elsewhere? How are deviations communicated across the network? Who controls the master data set? How early is the receiving site involved in process decisions?
These questions can matter as much as the individual technical capabilities being purchased.
CPHI’s 2026 outsourcing analysis makes the same point from another direction: mature pharma-CDMO relationships are increasingly supported by formal, multi-tier governance structures rather than ad hoc oversight.
The more strategic the outsourcing model becomes, the less plausible it is to manage it as a collection of purchase orders.
Specialisation inside integration
The distinction between the two models is also becoming less clean.
Large CDMOs are acquiring specialist capabilities. Specialist organisations collaborate with other specialists. Companies build networks of internal and external sites. M&A transactions increasingly target capabilities rather than simple manufacturing scale.
The result is a market where integration and specialisation can coexist.
A large CDMO may act as the programme integrator while relying on specialist centres of excellence inside its own network. A smaller provider may remain deeply specialised while collaborating with complementary organisations. Sponsors themselves may use an integrated partner for one asset and a specialist network for another.
The decision is increasingly programme-specific.
A conventional oral solid dose product with mature process knowledge presents a different outsourcing problem from an ADC, a viral vector or a highly potent injectable.
There is little reason to expect one sourcing architecture to fit all of them.
The better question
Perhaps one-stop shop or specialist? is therefore the wrong question.
The more useful question is: where does integration create value, and where does specialisation matter more?
Integration is valuable when handoffs create significant risk, when a programme needs speed across multiple stages or when the sponsor lacks the internal resources to coordinate several external partners.
Specialisation becomes more important when the technology itself is difficult, when the relevant expertise is scarce or when performance depends heavily on accumulated experience within a narrow field.
Most real programmes will sit somewhere between the two.
The outsourcing strategy then becomes an exercise in deciding which interfaces can safely be removed and which capabilities are too important to compromise.
The attraction of a one-stop shop is simplicity.
The attraction of a specialist is depth.
Modern pharmaceutical manufacturing increasingly requires both.
References
https://www.cphi-online.com/news/2026-outsourcing-outlook-update-pharma-at-a-crossroads-2
https://www.pharmasalmanac.com/articles/state-of-the-industry-2026-virtual-panel-small-molecules
https://www.pharmasalmanac.com/articles/state-of-the-industry-2026-virtual-panel-biologics
